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Abstract: Travoprost is a member of the prostaglandin analogue class of intraocular pressure 
(IOP)-lowering drugs used to treat ocular hypertension and glaucoma. Like other prostaglan-
din analogues, travoprost lowers IOP by enhancing the egress of aqueous humor through both 
the uveoscleral and trabecular outﬂ  ow channels. This review summarizes the published data 
regarding the safety and efﬁ  cacy of travoprost. Travoprost provides statistically signiﬁ  cant and 
clinically relevant reductions in mean IOP, of the order of 6.5–9.0 mmHg in most studies. In 
addition, travoprost provides consistent diurnal IOP control, with statistically signiﬁ  cant IOP 
reductions persisting up to 84 hours post-dose. Travoprost has a highly favorable safety proﬁ  le; 
most adverse events are cosmetic in nature (such as iris hyperpigmentation and eyelash growth), 
although more serious adverse events (such as iritis and macular edema) have been associated 
with travoprost and the other prostaglandin drugs. In some markets, travoprost is available in a 
ﬁ  xed combination with timolol; clinical studies have demonstrated that the ﬁ  xed combination 
– dosed once daily – lowers IOP by 7–11.5 mmHg. In conclusion, travoprost provides safe and 
effective reduction of IOP, with convenient once-daily dosing, supporting its role as primary 
monotherapy.
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Management issues in open-angle glaucoma 
and ocular hypertension
Open-angle glaucoma is an optic neuropathy characterized by progressive loss of 
retinal ganglion cells and their axons, resulting in progressive loss of the peripheral 
visual ﬁ  eld. Axonal loss is manifested as progressive thinning of the optic nerve head’s 
neuroretinal rim, producing the characteristic cupping of the nerve. If untreated or 
inadequately treated, glaucoma can lead to blindness.
The prevalence of open-angle glaucoma has recently been estimated at 1.9% in 
Americans over age 40 (Friedman et al 2004). This prevalence equates to approximately 
2.2 million affected individuals in the US in 2004, with an anticipated increase to 3.3 
million by the year 2020 (Friedman et al 2004). Worldwide, there will be an estimated 
60.5 million people with glaucoma by 2010 and 79.6 million by 2020 (Quigley and 
Broman 2006). Nearly half of all worldwide glaucoma will occur in Asians (47%), 
and open-angle glaucoma will account for 74% of all glaucoma by 2020; by 2010, 4.5 
million people worldwide will suffer bilateral blindness from open-angle glaucoma; 
this number will increase to 5.9 million by 2020 (Quigley and Broman 2006). 
The pathogenesis of open-angle glaucoma is incompletely understood. Numerous 
risk factors have been identiﬁ  ed. These include intraocular pressure, hispanic or black 
race, older age, positive family history of glaucoma, thinner central corneal thickness, 
and possibly myopia and diabetes mellitus. Lacking a clearly elucidated mechanism 
of disease to target therapeutically, treatment for glaucoma is aimed at risk factor Clinical Ophthalmology 2007:1(1) 12
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modiﬁ  cation. Of the risk factors listed above, intraocular 
pressure (IOP) is the only modiﬁ  able risk factor. Reduction 
of IOP is the only glaucoma therapy proven to be effective. 
IOP reduction has been shown to delay or prevent the devel-
opment of glaucoma in eyes with ocular hypertension (Kass 
et al 2002) and to prevent progression of glaucoma in eyes 
with (Heijl et al 2002) and without (Collaborative Normal 
Tension Glaucoma Study Group 1998a, b) elevated IOP.
IOP reduction can be achieved by topical and systemic 
medications, by various laser therapies, and by a number 
of incisional surgical techniques. Myriad medications in 
numerous drug classes are commonly used to achieve IOP 
reduction. Since ﬁ  rst introduced a decade ago, prostaglandins 
have rapidly become the preferred drug class for glaucoma 
management. The rapid rise in popularity of the prostaglan-
din analogues is largely due to the unrivalled efﬁ  cacy and 
safety of the drugs in this class, which include travoprost, 
latanoprost, and bimatoprost. 
The purpose of this review is to summarize the clinical 
data supporting the role of travoprost in the management of 
ocular hypertension and open-angle glaucoma.
Mechanism of action 
and pharmacokinetics
Intraocular pressure is determined by the balance between 
aqueous production and outﬂ  ow. The majority of aqueous 
outﬂ  ow is through the trabecular meshwork, with the re-
mainder egressing through the uveoscleral outﬂ  ow pathway 
in normal human eyes. Travoprost appears to lower IOP by 
facilitating aqueous outﬂ  ow through both the uveoscleral 
outﬂ  ow pathway and the trabecular outﬂ  ow pathway (Toris 
et al 2005, 2007).
Mechanism of action 
Travoprost, like the other prostaglandin analogues latanoprost 
and bimatoprost, is a synthetic analogue of prostaglandin F2α. 
Prostaglandins are a family of molecules found ubiquitously 
throughout most tissues and organs. They are synthesized en-
zymatically from fatty acids, and all contain 20 carbon atoms, 
including 5 in a ring formation. Their functions are diverse, 
and include roles in muscle constriction, inﬂ  ammation, and 
platelet aggregation. These various functions are mediated by 
binding of speciﬁ  c prostaglandins to one or more of numer-
ous prostaglandin receptors. The prostaglandin receptors are 
transmembrane, G-protein-coupled receptors.
The travoprost molecule is an ester pro-drug that is hydro-
lyzed by corneal esterases into its active free-acid form. The 
IOP-lowering efﬁ  cacy of all three prostaglandin analogues 
is dependent upon interaction with the prostaglandin FP re-
ceptor, as evidenced by the lack of IOP reduction seen with 
these drugs in eyes of FP receptor-deﬁ  cient mice (Crowston 
et al 2004, 2005; Ota et al 2005). Once hydrolyzed in the 
eye, travoprost acid then binds to prostaglandin FP recep-
tors in both the ciliary muscle (Sharif et al 2002) and the 
trabecular meshwork (Sharif et al 2003b). In cultured cells 
from both ciliary muscle and trabecular meshwork in human, 
rat, and mouse models, travoprost acid exhibits higher bind-
ing afﬁ  nity and higher potency at the FP receptor, and also 
demonstrates higher selectivity for the FP receptor than for 
other prostaglandin receptors, than either latanoprost or bi-
matoprost (Kelly et al 2003; Sharif et al 2002, 2003a, b, c).
FP-receptor binding by prostaglandin F2α and its ana-
logues results in numerous physiologic responses within cili-
ary muscle cells. These include phosphoinositide turnover, 
intracellular Ca2+ mobilization, and mitogen-activated protein 
(MAP) kinase activation (Sharif et al 2003c). In addition, 
FP receptor activation indirectly stimulates formation of 
cAMP via activation of the coupled G-protein by stimulat-
ing the synthesis of PGE2 (Yousufzai et al 1996; Zhan et al 
1998). This in turn leads to increased cellular levels of c-Fos 
and c-Jun within the nuclei of ciliary smooth muscle cells 
(Lindsey et al 1994). These two proteins can heterodimer-
ize, forming a complex that binds to the promoter regions 
of some genes, thus promoting their transcription (Karin et 
al 1997). The results of these FP receptor-mediated intracel-
lular signals include increased production of several matrix 
metalloproteinases (MMPs), speciﬁ  cally MMP-1, -2, -3 and 
-9, in cultured human ciliary smooth muscle cells (Lindsey 
et al 1997). MMPs are a family of enzymes that are capable 
of degrading all extracellular matrix components, including 
collagen. In monkey eyes, topical exposure to prostaglandin 
F2α reduces collagen types I, II, and IV within the ciliary 
muscle (Sagara et al 1999). Remodeling of the extracellular 
matrix of the ciliary body is hypothesized to lower IOP by 
creating or increasing spaces between the ciliary muscle ﬁ  ber 
bundles, thus increasing outﬂ  ow through the uveoscleral 
pathway (Schachtschabel et al 2000).
Pharmacokinetics 
The esterase-driven hydrolysis of travoprost to its free acid 
is rapid both in tissue and plasma. In rabbits, following a 
single topical dose of radiolabeled travoprost 0.004%, the 
drug distributes throughout all tissues and compartments of 
the eye, with higher concentrations in the cornea and lower 
concentrations in posterior segment tissues such as retina 
and choroid. Plasma levels are also detectable, and decline Clinical Ophthalmology 2007:1(1) 13
Travopost for open-angle glaucoma
in parallel with ocular tissue levels, with half-lives in these 
tissues of less than 2 hours. Topical ophthalmic application 
in humans results in systemic absorption with measurable 
plasma concentrations of both travoprost and travoprost 
acid (McCue et al 2002). Following one week of once daily 
dosing of travoprost 0.004%, peak plasma concentrations 
of travoprost acid up to 25 pg/mL were measured within 30 
minutes after dosing. Travoprost acid is rapidly cleared from 
plasma, with no measurable free acid in samples collected one 
hour after dosing; because of this short half-life, there is no 
evidence of accumulation of travoprost acid with once-daily 
dosing. To evaluate the presence of the travoprost pro-drug 
in plasma, selected samples underwent esterase hydrolysis 
and re-analysis of travoprost acid levels. Trace levels were 
identiﬁ  ed in some samples, more commonly in subjects 
treated with travoprost 0.004% versus 0.0015%, suggesting 
a dose-proportionality relationship. In addition, plasma levels 
of travoprost acid in subjects with mild, moderate and severe 
renal or hepatic impairment are not signiﬁ  cantly different 
from levels in normal subjects, indicating that travoprost 
dosing adjustments are unnecessary in patients with renal 
or hepatic impairment. 
Efﬁ  cacy results
Travoprost vs timolol
Phase III evaluation of travoprost’s safety and efﬁ  cacy 
consisted of three large clinical trials (Goldberg et al 2001; 
Netland et al 2001; Fellman et al 2002).
Goldberg et al (2001) randomized 573 patients with open-
angle glaucoma or ocular hypertension to treatment with ei-
ther travoprost 0.0015% or 0.004% once daily in the evening 
or timolol maleate 0.5% twice daily. Enrolled subjects had 
untreated IOP of at least 24 mmHg, with a mean IOP among 
all subjects of approximately 26 mmHg. After 9 months of 
treatment, mean IOP averaged across 6 study visits was lower 
with travoprost 0.004% than with timolol 0.5% at all time 
points (9 a.m., 11 a.m., and 4 p.m.) (p < 0.0246). Mean IOP 
reductions ranged from 8.0 to 8.9 mmHg with travoprost 
0.004% vs 6.3 to 7.9 mmHg with timolol 0.5%. 
Netland et al (2001) randomized 801 patients with 
open-angle glaucoma or ocular hypertension to one of 
four treatment regimens: travoprost 0.0015% once daily in 
the evening, travoprost 0.004% once daily in the evening, 
latanoprost 0.005% once daily in the evening, or timolol 
0.5% twice daily. Enrolled subjects had untreated IOP of 
at least 24 mmHg, with a mean IOP among all subjects of 
approximately 25–26 mmHg. After 12 months of treatment, 
mean IOP averaged across 7 study visits was lower with tra-
voprost 0.004% than with timolol 0.5% at all time points (8 
a.m., 10 a.m., and 4 p.m.) (p = 0.0001 for all). From similar 
mean baseline IOP levels of approximately 25.6 mmHg, 
mean IOP across visits and time points ranged from 17.7 to 
19.1 mmHg with travoprost 0.004% vs 19.4 to 20.3 mmHg 
with timolol 0.5%. 
Fellman et al (2002) randomized 605 patients with open-
angle glaucoma or ocular hypertension to treatment with ei-
ther travoprost 0.0015% or 0.004% once daily in the evening 
or timolol maleate 0.5% twice daily. Across all visits over 6 
months of treatment, mean IOP reductions ranged from 6.5 
to 8.0 mmHg with travoprost 0.004% vs 5.2 to 7.0 mmHg 
with timolol 0.5%. Of 13 scheduled IOP measurements over 
5 visits, IOP reduction with travoprost 0.004% was statisti-
cally superior to that seen with timolol 0.5% at 10 of the 13 
time points; at the remaining three time points, IOP reduction 
was still greater with travoprost 0.004% than with timolol 
0.5%, but these differences were not statistically signiﬁ  cant. 
Overall, travoprost 0.004% provided 0.9–2.4 mmHg more 
IOP reduction than timolol over all 13 time points. Patients 
receiving travoprost 0.004% were more likely to experience 
an IOP reduction of 25% or more compared to those receiving 
timolol 0.5% (62.0%–64.6% vs 37.6%–47.9%, respectively); 
this difference was particularly evident at 4 p.m. (64.6% vs 
37.6%, respectively).
Summarizing the Phase III data, travoprost used once dai-
ly lowers IOP by 6.5–9.0 mmHg when used as monotherapy. 
Travoprost is more effective than timolol in lowering IOP.
Travoprost vs other drugs
Several studies have evaluated the relative IOP reduction 
provided by the three prostaglandin analogues.
Netland et al (2001) included a latanoprost 0.005% arm 
in their Phase III evaluation of travoprost. Of 801 enrolled 
subjects with open-angle glaucoma or ocular hypertension, 
approximately 200 each were randomized to travoprost 
0.004% and latanoprost 0.005%. Mean IOP across all visits 
was comparable between the two drugs at 8 a.m. and 10 
a.m, but at 4 p.m., travoprost lowered IOP by a statistically 
signiﬁ  cant 0.8 mmHg more than latanoprost (p = 0.0191).
A prospective, cross-sectional, observational study with 
retrospective data collection compared the IOP-lowering 
efﬁ  cacy of travoprost and latanoprost (Denis et al 2006b). 
In the study, the time since last instillation and the time of 
IOP measurement were taken into consideration. Altogether, 
2052 patients treated with travoprost (n = 1704) or latano-
prost (n = 348) participated in the study. When the interval 
between the last treatment instillation and IOP measurement Clinical Ophthalmology 2007:1(1) 14
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(treatment/IOP interval) was <24 hours (n = 1241), 82% of 
travoprost-treated patients achieved pre-deﬁ  ned target IOPs 
compared with 67% for latanoprost patients (p < 0.0001). 
This difference was largest after 4 p.m., when the mean IOP 
was 16.5 mmHg for travoprost patients and 17.7 mmHg for 
latanoprost patients (p = 0.0025). When the treatment/IOP 
interval was >24 hours (n = 461), more patients using travo-
prost achieved the target IOP (78.5% vs 68.3%; p = 0.0344), 
and the mean IOP value was lower in the travoprost group 
(16.8 vs 17.8 mmHg; p = 0.0016).
Two studies compared the IOP-lowering effect of travo-
prost versus bimatoprost. In the ﬁ  rst, a small study by Cantor 
et al (2004), 26 subjects with primary open-angle glaucoma 
or ocular hypertension were randomized to treatment with 
either travoprost 0.004% or bimatoprost 0.03% once daily in 
the evening. After 6 months of treatment, mean IOP reduc-
tions across visits and time points for travoprost ranged from 
4.6 to 7.2 mmHg (19%–29%) vs 7.4–8.8 mmHg (34%–36%) 
for bimatoprost. These differences were not statistically sig-
niﬁ  cant (p > 0.057), possibly due to a small sample size and 
low power to detect differences. A larger, follow-up study 
of similar design was conducted by Cantor et al (2006), and 
enrolled 157 subjects. After 6 months of treatment, results of 
the larger study demonstrated mean IOP reductions with tra-
voprost and bimatoprost were 5.7 vs 7.1 mmHg, respectively, 
at 9 a.m. (p = 0.014); 5.2 vs 5.9 mmHg, respectively, at 1 p.m. 
(p = 0.213); and 4.5 vs 5.3 mmHg, respectively, at 4 p.m. 
(p = 0.207). Responder analysis revealed that statistically 
similar proportions of patients achieved IOP reductions of 
20% and 30%; investigator-determined clinical success 
(based on drug tolerability and achievement of target IOP) 
was statistically equivalent in both groups.
Parrish et al (2003) conducted a three-arm study com-
paring the three prostaglandin drugs head to head among 
410 subjects in a 12-week prospective, randomized trial. 
This group reported no differences in mean IOP reduction 
between travoprost (8.0 mmHg), latanoprost (8.7 mmHg), 
and bimatoprost (8.6 mmHg) (p = 0.128).
Franks et al (2006) compared the IOP reduction pro-
vided by travoprost with IOP reduction provided by the 
ﬁ  xed combination latanoprost 0.005%/timolol 0.5%. In 
this 6-week study, 110 subjects with open-angle glaucoma 
or ocular hypertension were randomized to receive either 
travoprost once daily in the evening or latanoprost/timolol 
once daily in the morning; masking was achieved by use of 
a placebo in the morning or evening, depending on random-
ization. There was no statistically signiﬁ  cant difference in 
IOP reduction between the two groups at any time point. 
Travoprost lowered IOP by 7.0 mmHg at 9 a.m. compared 
with 6.4 mmHg for latanoprost/timolol; at 5 p.m., IOP 
reductions for travoprost and latanoprost/timolol were 6.8 
and 6.1 mmHg, respectively.
Suzuki et al (2006) evaluated the relative IOP reduc-
tion with travoprost compared with the ﬁ  xed combination 
dorzolamide 2%/timolol 0.5%. Fifty-six subjects with open-
angle glaucoma or ocular hypertension were randomized to 
receive either travoprost once daily in the evening or dor-
zolamide/timolol twice daily; investigators but not subjects 
were masked to treatment. Mean IOP across all visits and 
time points was statistically lower with travoprost than with 
dorzolamide/timolol (p < 0.01). At 3 and 6 weeks, mean IOP 
with travoprost ranged from 7.1 to 7.5 mmHg, compared with 
4.5 to 4.8 mmHg with dorzolamide/timolol.
Summarizing the data comparing travoprost with other 
drugs, similar IOP reductions are seen with travoprost and 
latanoprost or bimatoprost, the other two members of the 
prostaglandin class of medications. Travoprost appears 
to be similar to ﬁ  xed combinations of timolol with either 
latanoprost or dorzolamide.
Travoprost and circadian IOP 
Circadian IOP variability has emerged as an independent 
risk factor for the progression of glaucoma (Asrani et al 
2000; Nouri-Mahdavi et al 2004). Therefore, the circadian 
IOP-lowering proﬁ  les of medications are a relevant measure 
of their clinical efﬁ  cacy. Several studies have evaluated the 
endurance of travoprost’s IOP-lowering effect over periods 
ranging from 24 to 84 hours post-dose.
Orzalesi et al (2006) conducted a comparison of the 
24-hour IOP-lowering proﬁ  les of travoprost, latanoprost 
and bimatoprost. In this crossover study, 44 subjects with 
primary open-angle glaucoma or ocular hypertension were 
sequentially treated with each of the three drugs for one 
month (with a one month washout between each), and under-
went 24-hour IOP assessments at pre-treatment baseline and 
after each month-long treatment session. This group found 
no statistically signiﬁ  cant differences in mean circadian IOP 
(measured in the sitting position using Goldmann applanation 
tonometry) between the three drugs. Travoprost produced a 
mean circadian IOP reduction of 7.1 mmHg, compared with 
6.7 mmHg for latanoprost and 7.9 mmHg for bimatoprost 
(p = 0.08). Supine IOP has recently been demonstrated to be 
generally higher than sitting IOP, and the ability to lower IOP 
in the supine position (i.e. while asleep at night) is another 
important aspect of a drug’s IOP-lowering proﬁ  le. The 
investigators also measured supine IOP using an electronic Clinical Ophthalmology 2007:1(1) 15
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tonometer, and found no differences in circadian IOP reduc-
tion between the three drugs in the supine position.
Dubiner et al (2004) conducted two studies evaluating the 
post-dose duration of IOP reduction produced by travoprost. 
In the ﬁ  rst, a small, uncontrolled and open-label pilot study, 
21 patients with open-angle glaucoma received travoprost 
once daily in the evening for 2 weeks. After the ﬁ  nal dose 
on the evening of the 14th day, IOP was assessed every four 
hours for 36 hours, then again at 60 and 84 hours post-dose. 
Peak IOP reductions from baseline were in the range of 
10.2–11.2 mmHg, and IOP remained statistically below base-
line levels throughout the entire 84 hours after the last dose 
(p < 0.001). Mean IOP reduction at 60 and 84 hours post-dose 
were 7.2 and 6.6 mmHg, respectively. In a follow-up study, 
35 patients with open-angle glaucoma were prospectively 
randomized to receive either travoprost or latanoprost once 
daily for two weeks in double-masked fashion; 34 patients 
completed the study. IOP was assessed every 4 hours after 
the last dose out to 44 hours post-dose. Both travoprost and 
latanoprost lowered IOP signiﬁ  cantly from untreated baseline 
at all time points (p  0.001). Latanoprost provided statisti-
cally lower IOP than travoprost (by 2.5 mmHg) 4 hours after 
the last dose (p = 0.04) and travoprost provided statistically 
lower IOP than latanoprost (by 3.3 mmHg) 24 hours after the 
last dose (p = 0.006). Travoprost also provided lower IOP 
than latanoprost (by 2.5 mmHg) at the 8PM IOP assessment 
immediately before the last dose (p = 0.041).
Garcia-Feijoo et al (2006) compared the duration of 
action of travoprost and latanoprost in 62 patients with 
primary open-angle glaucoma or ocular hypertension. In 
this prospective, randomized, double-masked trial, patients 
received once-daily treatment at 8 p.m. for 14 days, and then 
underwent sitting and supine IOP assessments (using Perkins 
tonometry) every 4 hours out to 48 hours post-dose. In the 
sitting position, travoprost produced lower mean IOPs than 
latanoprost in both the ﬁ  rst and second 24-hour periods after 
the last dose, but these differences did not reach the level of 
statistical signiﬁ  cance. In the supine position, IOP was lower 
in the travoprost group at every IOP measurement during the 
48 hours after the last dose; these differences reached statisti-
cal signiﬁ  cance at time points 12, 16, 20, 24, 36, 40, and 48 
hours after the last dose. Mean IOPs from the periods 0–24, 
24–48, and 0–48 hours post-dose were lower for travoprost 
than for latanoprost in the supine position (p < 0.05).
Sit et al (2006) conducted a prospective, open-label study 
of the duration of travoprost’s IOP-lowering effect in 20 
subjects with open-angle glaucoma or ocular hypertension. 
After a baseline, untreated, 24-hour circadian IOP curve was 
obtained, subjects used travoprost once daily in the evening 
for at least 4 weeks before undergoing a second 24-hour IOP 
curve on treatment. One to 8 weeks later, subjects discontin-
ued travoprost and presented for a third 24-hour IOP curve 
during hours 41–63 following the last dose of travoprost 
(off treatment). Daytime mean IOP values (between 7 a.m. 
and 11 p.m.) off treatment remained statistically lower than 
baseline but statistically higher than on-treatment daytime 
IOP measurements. Conversely, night-time mean IOP values 
(between 11 p.m. and 7 a.m.) remained statistically lower 
than baseline nighttime mean IOP values both on and off 
treatment, and the on- and off-treatment night-time mean 
IOP values were identical to one another. This suggests that 
travoprost’s prolonged duration of action is more pronounced 
at night than during the day. 
Summarizing the circadian data, travoprost’s duration 
of action exceeds its 24-hour dosing period. Statistically 
signiﬁ  cant and clinically relevant reductions from baseline 
are seen up to 63 hours after the last dose of travoprost. Com-
pared with latanoprost, travoprost appears to provide better 
IOP control at the end of each dosing period. The product is 
labeled for dosing once daily in the evening.
The ﬁ  xed combination travoprost/
timolol
Fixed combinations of all three prostaglandin analogues 
– travoprost, latanoprost, and bimatoprost – and timolol have 
been developed by their respective manufacturers. 
The ﬁ  xed combination travoprost 0.004%/timolol 0.5% 
has been studied by several investigators. Barnebey et al 
(2005) enrolled 263 patients with open-angle glaucoma or 
ocular hypertension into a randomized, multicenter, double-
masked trial comparing the ﬁ  xed combination dosed once 
daily in the morning with monotherapy with either travoprost 
0.004% once daily in the evening or timolol 0.5% twice 
daily. After 3 months, the ﬁ  xed combination lowered IOP by 
1.9–3.3 mmHg more than timolol monotherapy (p  0.003), 
and by 0.9–2.4 mmHg more than travoprost monotherapy 
(p < 0.05). The ﬁ  xed combination lowered IOP statistically 
more than travoprost monotherapy at 7 of 9 IOP assess-
ments during the study. IOP reductions from baseline were 
in the range of 8.8–11.5 mmHg for the ﬁ  xed combination, 
7.7–9.3 for travoprost, and 6.7–8.7 for timolol across visits 
and time points.
Schuman et al (2005) compared the ﬁ  xed combination 
once daily in the morning to concomitant therapy with tra-
voprost once daily in the evening and timolol twice daily. 
A third arm received only timolol twice daily. In this pro-Clinical Ophthalmology 2007:1(1) 16
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spective, randomized, double-masked, multicenter trial, 403 
subjects with open-angle glaucoma or ocular hypertension 
were enrolled. After 3 months, the ﬁ  xed combination lowered 
IOP more from baseline than timolol monotherapy at every 
visit and time point. In contrast, the concomitant dosing of 
the separate components produced statistically signiﬁ  cantly 
more IOP reduction from baseline at 2 of 9 time points, with 
equivalent reductions at the remaining 7 time points. IOP 
reductions from baseline were in the range of 6.8–8.6 mmHg 
for the ﬁ  xed combination, 7.3–8.4 mmHg for travoprost and 
timolol concomitant therapy, and 4.6–7.0 mmHg for timolol 
across visits and time points.
Hughes et al (2005) also compared the travoprost/timo-
lol ﬁ  xed combination with concomitant use of travoprost 
and timolol. In this prospective, randomized, multicenter, 
double-masked trial, 316 subjects with open-angle glaucoma 
or ocular hypertension were assigned to treatment either with 
the ﬁ  xed combination dosed once daily in the morning, or 
with the concomitant administration of travoprost once daily 
in the evening and timolol once daily in the morning. After 3 
months, the upper 95.1% conﬁ  dence limit for the difference 
in mean IOP between the two treatment groups was within 
+1.5 mmHg at 7 of 9 time points, supporting non-inferiority 
of the ﬁ  xed combination compared with concomitant dosing 
at most time points. The two time points that fell outside this 
non-inferiority range were both at 10 a.m. on separate visits. 
IOP reductions from baseline were in the range of 7.4–9.4 
mmHg for the ﬁ  xed combination and 8.4–9.4 mmHg for 
travoprost and timolol concomitant therapy.
In both of the concomitant vs ﬁ  xed combination studies, 
concomitant therapy was more effective at several time points 
than the combination. This may be attributable to differences 
in dosing regimens, in which the prostaglandin is given in the 
morning in the ﬁ  xed combination group and in the evening 
in the concomitant group. Prostaglandins are recommended 
for evening rather than morning dosing. This is partly in an 
effort to reduce the clinical signiﬁ  cance of the transient con-
junctival hyperemia that occasionally follows topical dosing 
(see Safety and Tolerability below). In contrast, beta-blockers 
generally lower IOP more effectively with morning rather 
than evening dosing (Ong et al 2005) as a consequence of 
the natural reduction of aqueous production at night (Reiss 
et al 1984) which essentially requires morning dosing for 
the ﬁ  xed combination.
Denis et al (2006a) have evaluated the efﬁ  cacy of the 
travoprost/timolol ﬁ  xed combination when dosed in the 
morning versus evening. In this prospective, randomized, 
double-masked trial, 92 subjects with open-angle glaucoma 
or ocular hypertension received the ﬁ  xed combination either 
in the morning or the evening for 6 weeks. IOP reductions 
were similar in both groups, ranging from 16.5 to 16.7 mmHg 
in the morning group and 16.1 to 17.2 mmHg in the evening 
group. IOP reductions from baseline were statistically sig-
niﬁ  cant and clinically relevant in both groups, with mean 
IOP reductions of 8–10 mmHg (32%–38%).
The travoprost/timolol ﬁ  xed combination has been ap-
proved in the EU, Canada, and Australia, but has not been ap-
proved by the US Food and Drug Administration to date.
Safety results
The side-effects of the prostaglandin analogues have re-
cently been reviewed elsewhere (Hollo 2007). The adverse 
effects associated with travoprost have been identiﬁ  ed both 
in large clinical trials and in small series and case reports. 
Without exception, the adverse effects seen with travoprost 
therapy are identical in nature to those associated with all 
other members of the prostaglandin analogue class of IOP-
lowering medications. Although most of these adverse ef-
fects do not pose a threat to vision or health, a few potential 
safety issues have been identiﬁ  ed. Among the former are 
conjunctival hyperemia, iris hyperpigmentation, eyelash 
changes, and periocular hyperpigmentation; and among the 
latter are the possibility of iritis and/or macular edema. Each 
of these potential adverse effects has been reported with at 
least one of the prostaglandins analogues. In the following 
section, travoprost’s relationship with each of these events 
will be discussed.
Conjunctival hyperemia
The incidence of hyperemia ranged from 32.5% to 49.5% for 
travoprost 0.004% vs 7% to 14% for timolol maleate 0.5%. 
In most cases, the hyperemia was trace to mild in severity, 
and discontinuation from the study was uncommonly (< 5%) 
due to hyperemia (Goldberg et al 2001; Netland et al 2001; 
Fellman et al 2002). In at least one study, the hyperemia 
improved over time with continued dosing (Goldberg et al 
2001).
The relative incidence of hyperemia between prostaglan-
dins has also been evaluated. Netland et al (2001) reported a 
27.6% incidence of hyperemia in eyes receiving latanoprost 
versus 49.5% in travoprost-treated eyes. Cantor et al (2006) 
reported hyperemia in 21.1% of eyes receiving bimatoprost 
vs 14.8% in travoprost-treated eyes. In the three-way head-
to-head trial reported by Parrish et al (2003), the incidences 
of hyperemia for travoprost, latanoprost, and bimatoprost 
were 58%, 68.6%, and 47.1%, respectively. Also, in a trial Clinical Ophthalmology 2007:1(1) 17
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by Lewis et al (2007), comparing travoprost with BAK with 
travoprost without BAK, the incidences of subject-reported 
hyperemia were 9.0% and 6.1%, respectively.
The reported rates of conjunctival hyperemia vary 
signiﬁ  cantly even for individual drugs. This likely is a result 
of non-standardized methods for evaluating hyperemia. 
Methodologies for evaluating hyperemia in these studies 
ranged from patient complaint to subjective investigator 
grading of hyperemia based on tiered scoring systems to 
photographic evaluation using internal color strips in the im-
ages to account for differences in photographic techniques 
between individuals. To date, there has been no evidence 
supporting that conjunctival hyperemia poses a threat to 
vision or health, and that this adverse effect is simply a 
cosmetic issue.
Iris hyperpigmentation
Darkening of the iris is a well-established consequence of 
therapy with all three of the prostaglandin analogues. The 
incidence varies from study to study based on differences in 
methodology, as with conjunctival hyperemia. In the three 
Phase III registry trials, the incidence of iris hyperpigmen-
tation in eyes treated with travoprost 0.004% ranged from 
1.0–3.6% versus 0% of timolol-treated eyes (Goldberg et al 
2001; Netland et al 2001; Fellman et al 2002).
In the study by Netland et al (2001), 5.2% of eyes receiv-
ing latanoprost, vs 3.1% of eyes receiving travoprost, devel-
oped iris hyperpigmentation. Cantor et al (2006) reported a 
single case of iris hyperpigmentation in their 157-subject 
comparison of travoprost vs bimatoprost; it occurred in a 
bimatoprost-treated eye. 
The incidence of iris hyperpigmentation in these 
relatively short (6–12 months) studies is low. The long-term 
incidence of iris hyperpigmentation was evaluated for 
latanoprost in a prospective, open-label study, consisting of 
a three-year initial phase (n = 519) and a 2-year extension 
(n = 380) (Alm et al 2004). Overall, 33.4% of eyes experi-
enced a change in eye color with up to 5 years of exposure 
to once-daily latanoprost. Time-course analysis revealed that 
74% of eyes experiencing iris hyperpigmentation manifested 
the change within the ﬁ  rst 8 months of treatment, and 94% 
within the ﬁ  rst 24 months, with no additional new cases noted 
beyond month 36 of treatment. 
The risk of experiencing iris hyperpigmentation appears 
to depend on baseline eye color. Green and mixed hazel 
eyes are at greatest risk, while blue and grey eyes appear to 
be infrequently affected. In the 5-year study of latanoprost 
conducted by Alm et al (2004), no subjects with brown or 
blue/grey eyes were affected, while more than 75% of green-
brown or yellow-brown eyes were affected.
This clinical observation regarding eye color and risk of 
iris hyperpigmentation is consistent with histopathological 
studies demonstrating that topical prostaglandin therapy 
induces an increase in melanin production within existing 
melanocytes, with no evidence of melanocyte proliferation 
(Pfeiffer et al 2001, 2003; Cracknell et al 2003; Albert et al 
2004; Arranz-Marquez et al 2004). Of these, the most robust 
evaluation was by Albert et al (2004), who undertook a large, 
masked histopathological evaluation of 449 latanoprost-
exposed iris specimens compared with 142 control speci-
mens. There was no evidence of malignancy or pre-malignant 
changes in any specimen. Latanoprost-treated eyes had more 
iris freckles than controls (35% vs 20.6%, p = 0.001); the 
authors stated that in their opinion, they “do not believe that 
the increase in iris freckles has malignant potential or can 
lead to any adverse clinical effects on the eye”. They pos-
tulated that these freckles were focal manifestations of iris 
hyperpigmentation. Using immunohistochemical staining, 
they reported “no signiﬁ  cant difference in mean melanocyte 
counts…between the latanoprost-treated and control groups”. 
They concluded that iris hyperpigmentation in latanoprost-
treated eyes was “due to an increased amount of melanin 
within the iris stromal melanocytes”.
As with conjunctival hyperemia, iris hyperpigmentation 
associated with travoprost therapy appears to be a cosmetic 
issue that poses no known threat to vision or health. The 
incidence appears to be low – below 5% – in studies involv-
ing up to one year of daily exposure to travoprost 0.004%. 
The potential for eye color changes should be discussed with 
patients prior to the initiation of treatment, but in practice, 
patients rarely express concern regarding the possibility of 
this adverse event, and rarely self-report changes in eye color 
despite long-term therapy with these drugs. Greater caution 
should be employed in cases where monocular treatment is 
required, as unilateral iris hyperpigmentation may have a 
greater cosmetic impact than bilateral. This issue is easily 
overlooked after successful unilateral ﬁ  ltering surgery, in 
which preoperative bilateral prostaglandin therapy becomes 
unilateral therapy upon discontinuation of treatment in the 
operated eye. 
Eyelash changes
Travoprost and the other prostaglandin analogues can induce 
speciﬁ  c changes in the appearance of the eyelashes, including 
lengthening, thickening, and darkening of the lashes, as well 
as an increase in the number of lashes. These changes are Clinical Ophthalmology 2007:1(1) 18
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common in eyes treated with all three drugs (Goldberg et al 
2001; Netland et al 2001; Fellman et al 2002).
Based on these trials, a majority of patients treated with 
travoprost for at least 6 months can anticipate some degree 
of lash changes. These changes appear to be cosmetic in 
nature and do not pose a threat to vision or health. Based 
on the similar incidences of lash changes for travoprost at 6 
(Fellman et al 2002), 9 (Goldberg et al 2001), and 12 months 
(Netland et al 2001) it appears that lash changes generally 
manifest within the ﬁ  rst 6 months of therapy.
Periocular hyperpigmentation
Eyelid hyperpigmentation has been reported in association 
with the use of latanoprost (Kook and Lee 2000; Wand 
et al 2001a, b; Herndon et al 2003) and bimatoprost (Herndon 
et al 2003; Herane and Urbina 2004; Galloway et al 2005) 
and was also observed in regulatory trials with travoprost 
(Golberg et al 2001; Netland et al 2001; Fellman et al 2002). 
Eyelid hyperpigmentation appears to be a rare side-effect of 
the prostaglandin class of IOP-lowering medications. Based 
on limited histopathological data from Kapur et al (2005), 
the mechanism of eyelid hyperpigmentation appears similar 
to that of iris hyperpigmentation, characterized by increased 
melanogenesis and not melanocyte proliferation; the inves-
tigators concluded that prostaglandin-induced eyelid hyper-
pigmentation “occurs from increased melanogenesis…with 
the absence of melanocyte proliferation and melanocyte 
atypia”. Unlike iris hyperpigmentation, hyperpigmenta-
tion of the eyelid appears to improve (Kook and Lee 2000; 
Wand et al 2001b; Herndon et al 2003; Herane and Urbina 
2004; Galloway et al 2005) – and in some cases resolve 
completely (Galloway et al 2005) – upon discontinuation of 
the drug. All existing data to date support that these changes 
are solely cosmetic in nature, and have not posed a health 
risk in any form.
Iritis
Iritis is infrequently reported in association with use of the 
prostaglandin drugs, and the causal relationship between use 
of these drugs and the occurrence of intraocular inﬂ  ammation 
has been debated. The association between prostaglandins 
and iritis was reported by several groups, including Fechtner 
et al (1998), who reported 5 eyes of 4 patients who developed 
iritis after beginning therapy with latanoprost, recovered after 
discontinuation of the drug, and experienced recurrent iritis 
upon rechallenge. The incidence of latanoprost-induced iritis 
was determined retrospectively in a cohort of 94 patients by 
Warwar et al (1998), who reported iritis in 8 eyes of 6 patients 
(4.9% of eyes, 6.4% of patients) treated with latanoprost. 
Three of the 6 patients were rechallenged, and 2 manifested 
recurrent iritis. Bimatoprost has also been reported to cause 
iritis (Packer et al 2003; Parentin 2003). Travoprost can also 
induce iritis, as reported by Kumarasamy and Desai (2004) in 
which iritis appeared after initiating therapy with travoprost 
and resolved with discontinuation.
To determine the relative effects of the three prostaglan-
din analogues on the integrity of the blood-aqueous barrier, 
Cellini et al (2004) evaluated anterior chamber and cell and 
ﬂ  are values in 60 glaucoma patients randomly assigned to 
treatment with travoprost, latanoprost, or bimatoprost for six 
months. The researchers employed a ﬂ  are meter to quantify 
both cell and ﬂ  are at baseline and after 3 and 6 months of 
therapy. All 3 drugs were associated with statistically sig-
niﬁ  cant increases in cell and ﬂ  are from baseline at 3 and 6 
months, with little diminution of cell or ﬂ  are from 3 to 6 
months. Latanoprost induced signiﬁ  cantly more cell and 
ﬂ  are than either travoprost or bimatoprost at 3 and 6 months. 
Travoprost induced more cell and ﬂ  are than bimatoprost 
at 3 months, but by 6 months the levels were statistically 
equivalent.
In the study by Cellini et al (2004), the phakic status of 
the eyes of participating subjects was not described. Arcieri 
et al (2005) recently performed a similar trial in 34 phakic 
individuals. In a crossover design, subjects received each 
drug (travoprost, latanoprost, and bimatoprost) for 4 weeks 
with a 4-week washout between each crossover. In these 
phakic eyes, there was no increase from baseline in anterior 
chamber ﬂ  are with any of the 3 drugs, nor any between-drug 
differences in ﬂ  are levels.
Symptomatic iritis appears to be an uncommon adverse 
event associated with all three prostaglandin analogues. The 
course is generally mild and the inﬂ  ammation resolves upon 
discontinuation of the drug with or without anti-inﬂ  ammatory 
therapy. Interestingly, a signiﬁ  cant proportion of the eyes 
in the studies referenced above had either a prior history of 
iritis or had risk factors (such as prior cataract surgery with 
or without complications) predisposing to iritis. From these 
observations, the use of prostaglandin analogues in eyes 
with a history of iritis, or with risk factors for iritis, should 
occur with caution. Also, based on the high rates of positive 
rechallenges, reinitiating therapy after an episode of iritis 
may not be advisable.
Macular edema
Macular edema was not noted as a side-effect of the prosta-
glandins in Phase III trials, but as with iritis, post-marketing Clinical Ophthalmology 2007:1(1) 19
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reports have suggested a relationship that has been debated. 
Case reports and small series of macular edema have been 
reported in association with all 3 prostaglandin analogues 
(Carrillo and Nicolela 1994; Ayyala et al 1998; Callanan 
et al 1998; Gaddie and Bennett 1998; Moroi et al 1999; 
Wand et al 2001a, b; Tokunga et al 2002; Jager and Jonas 
2003; Watanabe et al 2003; Del Hierro et al 2004; Altintas 
et al 2005). Virtually all of these cases included eyes with 
other risk factors for macular edema, most commonly prior 
cataract surgery (both complicated and uncomplicated). In 
cases where post-discontinuation outcomes were reported, 
macular edema resolved, and visual acuity returned to 
baseline, upon discontinuation of the prostaglandin with 
or without anti-inﬂ  ammatory treatment (Ayyala et al 1998; 
Moroi et al 1999; Wand et al 2001a; Tokunaga et al 2002; 
Jager and Jonas 2003; Watanabe et al 2003; Carrillo and 
Nicolela 2004; Altintas et al 2005).
The incidence of macular edema in eyes treated with 
latanoprost was reported by Warwar et al (1998). In their 
cohort of 163 predominantly phakic eyes of 94 patients, 
2 eyes of 2 patients developed macular edema (1.2% of 
eyes, 2.1% of patients). Lima et al (2000) reported an 
incidence of 2.2% among 185 pseudophakic or aphakic 
patients treated with latanoprost. Yeh et al (2002) found 
an incidence of 3.0% in 134 pseudophakic eyes treated 
with latanoprost after uncomplicated cataract surgery 
and with no history of or risk factors for macular edema. 
In contrast, Furuichi et al (2001) reported no increase 
in macular thickness, as measured by optical coherence 
tomography, in 68 eyes of 38 glaucoma patients treated 
with latanoprost who had no history of intraocular surgery 
or other risk factors for macular edema.
The true cause of macular edema in eyes receiving 
latanoprost therapy has been extensively evaluated by 
Miyake et al (1999). In an early study of 145 glaucomatous 
or ocular hypertensive eyes scheduled for elective cataract 
surgery, eyes receiving latanoprost for 5 weeks postopera-
tively developed more angiographic macular edema than 
eyes receiving placebo, and diclofenac was more effective 
than ﬂ  uorometholone in suppressing latanoprost-associated 
macular edema. On closer inspection, however, the latano-
prost vehicle, and particularly the preservative – BAK – was 
suspected to be the causal factor in inducing macular edema. 
In a follow-up study, the incidence of macular edema follow-
ing cataract surgery was equivalent in eyes receiving timolol 
maleate solution preserved with BAK and in eyes receiving 
timolol vehicle with BAK, and was signiﬁ  cantly lower in 
eyes receiving timolol vehicle without BAK (Miyake et al 
2001). These observations led Miyake et al (2003) to coin the 
term “pseudophakic preservative maculopathy” in an effort 
to clarify that macular edema can arise in association with 
treatment with any BAK-preserved topical medication.
In summary, macular edema can occur as a rare side-
effect in eyes treated with travoprost or other prostaglandin 
analogues. Pseudophakic eyes and eyes with other risk 
factors for macular edema are most likely to be affected, 
and phakic eyes without risk factors may not be at risk. The 
edema resolves, and visual acuity returns, upon cessation of 
prostaglandin therapy.
Systemic safety
Travoprost, like all members of the prostaglandin class 
of IOP-lowering medications, is extremely well-tolerated 
systemically. In Phase III clinical trials with travoprost, no 
systemic side effects were noted to occur statistically more 
often in travoprost-treated subjects than in subjects treated 
with timolol (Goldberg et al 2001; Netland et al 2001; 
Fellman et al 2002) or latanoprost (Netland et al 2001). 
In addition, post-marketing surveillance has not revealed 
any unanticipated systemic adverse events associated with 
travoprost or other prostaglandin analogues. Travoprost has 
no appreciable effect on the cardiovascular or pulmonary 
systems, and does not alter hematology, blood chemistry, or 
urinalysis laboratory values (Inan et al 2004).
Travoprost is classiﬁ  ed as a pregnancy category C drug. 
Travoprost was teratogenic in rats receiving 250 times the 
maximum recommended human ocular dose (MRHOD) but 
not at 75 times the MRHOD, but a higher risk of fetal loss 
was noted with the latter dose. The package insert advises that 
“there are no adequate and well-controlled studies in pregnant 
women,” and recommends that the drug be used in pregnant 
women “only if the potential beneﬁ  t justiﬁ  es the potential 
risk to the fetus” (Alcon Laboratories, Inc, 2006) 
Patient-focused considerations
Quality of life 
Quality of life (QOL) assessments with glaucoma patients 
can be accomplished by using one or more of a number of 
different instruments that are available (Spaeth et al 2006).
However, the impact on QOL of decreased vision as an 
outcome of uncontrolled IOP and progressing glaucoma 
disease typically occurs over a long period of time. The 
consequences of reduced vision are serious but patients 
are also focused on the things that currently impact their 
daily life such as how satisﬁ  ed they are with their treatment 




The Treatment Satisfaction Survey for Intraocular Pressure 
(TSS-IOP) was developed to identify factors associated with 
patient satisfaction with glaucoma therapy. The instrument 
queries patients receiving IOP-lowering therapy on issues 
pertaining to various aspects of glaucoma management and 
topical medical therapy, and was recently validated in 250 
subjects with glaucoma or ocular hypertension (Atkinson 
et al 2003; Day et al 2006). In this study, patient satisfaction 
positively correlated with effectiveness of therapy, lack of 
side effects, and ease and convenience of use. Of note, travo-
prost and the other prostaglandin analogues are characterized 
by each of these satisfaction-promoting characteristics, with 
unrivaled safety and efﬁ  cacy, as well as convenient once-
daily dosing.
Looking at satisfaction from an economic point of view, 
Jampel et al (2003, 2005) conducted a pair of studies to 
determine both patients’ and physicians’ willingness to pay 
for speciﬁ  c characteristics of an IOP-lowering medication. 
Their ﬁ  ndings were insightful. One hundred thirteen mem-
bers of the American Glaucoma Society were presented with 
a hypothetical IOP-lowering drug costing US$50 per month 
and asked how much, if at all, they would be willing to pay 
to improve speciﬁ  c aspects of the drug (Jampel et al 2005). 
For instance, assuming that the $50 drug caused a mild bad 
taste in the mouth, 91% of glaucoma specialists were willing 
to pay an average of $81 (a $31 premium) to avoid the bad 
aftertaste. In the study, the top attributes worth paying extra 
to avoid were as follows: 100% of physicians were willing 
to pay more (mean $92) for a drug that did not cause blurred 
vision; 99% would pay more (mean $105) to avoid sexual 
performance side-effects; 98% would pay more (mean $87) 
to reduce dosing from 3 times daily to once daily; and 97% 
would pay more (mean $92) to avoid drowsiness. In contrast, 
the following were the attributes least concerning to physi-
cians: only 48% would pay more (mean $79) to avoid a small 
risk of iris hyperpigmentation; 60% would pay more (mean 
$69) for a drug available in generic form; and 88% would 
pay more (mean $71) for a combination product that reduced 
a two-bottle regimen to a one-bottle regimen.
The same scenarios were presented to 230 glaucoma 
patients in 4 distinct practices (Jampel et al 2003), and 
the differences in their valuations of these drug attributes, 
compared to physicians, are remarkable. The top 5 attributes 
patients wished to avoid (with % willing to pay more to 
avoid that attribute, and the mean amounts they were will-
ing to pay to avoid it) were as follows: blurred vision (85%, 
$71); drowsiness (83%, $69); bad aftertaste (76%, $66); and 
stinging/tearing upon instillation (72%, $62). The attributes 
for which patients were least willing to pay extra to avoid 
were: availability of a generic (26%, $54); reduction from 3 
times daily to twice daily dosing (38%, $56); a combination 
product eliminating one bottle of medication (43%, $58); 
reduction from 3 times daily to once daily dosing (59%, $63); 
and sexual performance side-effects (59%, $68).
The attributes patients want most to avoid – blurred 
vision, drowsiness, bad aftertaste, and stinging upon in-
stillation – are all uncommon with travoprost and other 
prostaglandin analogues. Interestingly, there is something 
Table 1 Summary of key travoprost monotherapy efﬁ  cacy data
Study  Comparator  No. of subjects  Summary of ﬁ  ndings
Goldberg et al 2001  Timolol  573  Mean IOP lower with travoprost than timolol 
      at all time points (p  0.0246)
Netland et al 2001  Timolol  801  Mean IOP lower with travoprost than 
      timolol across all time points (p = 0.0001)
Netland et al 2001  Latanoprost  801  Mean IOP similar at 8 a.m. and 10 a.m. but lower 
      at 4 p.m. with travoprost than latanoprost (p = 0.0191)
Fellman et al 2002  Timolol  605  Mean IOP lower with travoprost than timolol 
      at 10 of 13 time points (p  0.03)
Denis et al 2006a, b  Latanoprost  2052  More eyes reached target IOP with 
      travoprost than latanoprost (p  0.0344)
Cantor et al 2004, 2006  Bimatoprost  157  Mean IOP similar at 1 p.m. and 4 p.m. but 
      lower with bimatoprost than travoprost at 9 a.m. (p = 0.014)
Parrish et al 2003  Latanoprost  410  Mean IOP similar with both drugs (p > 0.05)
Parrish et al 2003  Bimatoprost  410  Mean IOP similar with both drugs (p > 0.05)
Franks et al 2006  Latanoprost/Timolol  110  Mean IOP similar with both drugs (p > 0.05)
Suzuki et al 2006  Dorzolamide/Timolol  56  Mean IOP lower with travoprost than dorzolamide/timolol (p < 0.01)
Abbreviations: IOP, intraocular pressureClinical Ophthalmology 2007:1(1) 21
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of a disconnect between what physicians and patients value 
in a medication. Physicians put great value on once-daily 
dosing and avoidance of sexual side-effects, while these are 
of considerably less relative concern to patients. Conversely, 
while physicians are willing to tolerate mild stinging and 
tearing upon instillation, this is highly bothersome to patients. 
These insights may be of value to physicians when develop-
ing treatment plans for their patients.
Therapeutic compliance 
Compliance assessment in glaucoma has evolved in recent 
years. New terms such as adherence and persistency have 
been introduced. Persistency is an indirect measure of com-
pliance derived from prescription reﬁ  ll rates. The information 
is obtained not from the patient or physician, but from man-
aged care databases in which members have a single central 
source for prescription drugs. Persistency is a measure of the 
time from initial prescription until the patient stops reﬁ  lling 
the medication. As a result, low persistency can arise either 
from patient noncompliance or from physicians making 
changes in therapy, and is a useful parameter by which to 
gauge the length of time a drug is used or useful before either 
the patient or physician discontinues its use.
Persistency with glaucoma medications has been mea-
sured in several studies. Wilensky et al (2006) studied per-
sistency in over 2000 glaucoma patients on prostaglandin 
therapy. Of patients who persisted for at least 3 months upon 
beginning treatment, the percentages of patients still on the 
same treatment 12 months after starting therapy were 70.6% 
for travoprost, 69.4% for latanoprost, and 68.1% for bima-
toprost. While these data suggest comparable persistency 
among the various prostaglandin analogues, a second study 
did not conﬁ  rm this. 
In a different twist on persistency with initial prosta-
glandin therapy, patients in the Medco Health database who 
initiated prostaglandin therapy were followed if they were 
still taking their initial prostaglandin at 12 months. Overall, 
39% of travoprost patients needed to add a second glaucoma 
medication within that 12-month time period compared with 
39% of bimatoprost patients and 51% of latanoprost patients 
(p < 0.0001). This relative difference was consistent when 
looking at the subsets of patients’ naïve to glaucoma therapy 
and those using a non-prostaglandin drug before they started 
using prostaglandin therapy (Covert and Robin 2006).
Recently, Alcon Laboratories (manufacturers of travo-
prost) have developed and introduced an electronic dosing aid 
designed to remind patients to take their drops, to facilitate 
instillation of drops, and to record each administered dose 
for compliance monitoring. The device is a small housing 
into which a commercial bottle of travoprost is placed. The 
device is programmable to remind patients to dose at their 
preferred time, with ﬂ  ashing lights or an audible beeping 
alarm or both. The device has a lever that is calibrated to 
dispense a single drop of travoprost when pressed; this lever 
may be helpful to patients with arthritis or tremors who have 
difﬁ  culty squeezing the small bottle with appropriate force 
to dispense a single drop. Additionally, the device electroni-
cally records the date and time of each activation of the lever. 
When returned to the physician’s ofﬁ  ce, the device is placed 
in a docking cradle attached to a computer, and the provided 
software generates a dosing schedule.
The dosing aid was recently evaluated in a study by 
Boden and colleagues (2006). Ten volunteers used the device 
to instill artiﬁ  cial tears over 15 days; each was assigned a 
schedule designed to mimic compliance rates ranging from 
50% to 100% compliance. Participants recorded their dos-
ing schedule in a journal, which was then compared with 
the electronic device’s compliance report. They found that 
date stamping was 100% accurate, and time stamping was 
generally accurate to within +20 minutes. The device failed to 
record at least one drop in 70% of patients, suggesting that the 
device may provide an underestimate of true compliance.
Conclusions/place in therapy
Travoprost is an effective IOP-lowering medication, 
providing 6.5–9.0 mmHg of IOP reduction when used as 
Table 2 Summary of key travoprost safety data
Safety event  Incidence in eyes treated   References
 with  travoprost
Conjunctival hyperemia  32.5%–49.5%  Goldberg et al 2001; Netland et al 2001; Fellman et al 2002
Iris hyperpigmentation  1.0%–3.6%  Goldberg et al 2001; Netland et al 2001; Fellman et al 2002
Eyelash changes  51%–76.2%  Goldberg et al 2001; Netland et al 2001, Fellman et al 2002
Periocular hyperpigmentation  Rare  Goldberg et al 2001; Netland et al 2001; Fellman et al 2002
Iritis  Rare  Kumarasamy and Desai 2004
Macular edema  Rare  Del Hierro et al 2004Clinical Ophthalmology 2007:1(1) 22
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monotherapy. Its efﬁ  cacy is equivalent to other drugs in the 
prostaglandin class, and at least as effective as combination 
products pairing timolol with latanoprost or dorzolamide. 
Travoprost may have added efﬁ  cacy in black patients and 
eyes with pseudoexfoliation, and post-marketing studies 
have demonstrated its efﬁ  cacy in eyes with chronic angle 
closure glaucoma, and following cataract surgery, although 
the product is not speciﬁ  cally indicated for these latter two 
conditions. Its duration of action is longer than its 24-hour 
dosing period, with signiﬁ  cant IOP reductions from baseline 
as long as 63 hours after the last dose, but once-daily dos-
ing is recommended. The data suggest that travoprost pro-
vides greater IOP control at the end of each dose than does 
latanoprost. Travoprost’s established ocular side-effects are 
generally cosmetic in nature (conjunctival hyperemia, iris 
and eyelid hyperpigmentation, eyelash changes), with few 
reports of iritis and macular edema; side-effects of travoprost 
are similar to side-effects of other prostaglandin drugs, sup-
porting that these are class effects. Given its excellent safety 
and efﬁ  cacy proﬁ  le, its convenient once-daily dosing, and 
its widespread global availability, travoprost is commonly 
used as ﬁ  rst-line therapy for glaucoma (although currently 
only indicated for second-line therapy in the US). Five years 
of post-marketing surveillance in the United States, where it 
ﬁ  rst gained regulatory approval in 2001, has conﬁ  rmed the 
safety and efﬁ  cacy results of Phase III trials, and supports 
its role as primary monotherapy.
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